Evaluation of the diagnostic value of a three-miRNA panel in prostate cancer: a discovery and validation study
A three-microRNA panel has an important diagnostic value in prostate cancer and is expected to serve as diagnostic biomarker for prostate cancer. Furthermore, the genes FAM107A and TAF1C may be potential therapeutic targets for prostate cancer.
Authors
- Yongqing Lai
- Chen Sun (ORCID: https://orcid.org/0000-0002-5145-1536)
- Yingqi Li (ORCID: https://orcid.org/0009-0007-6169-405X)
- Xionghui Wu
- Huimei Zhou (ORCID: https://orcid.org/0009-0008-5085-6110)
- Zhenjian Ge
- Pengwu Zhang
- Shengjie Lin
- Xutai Li
- Yutong Wu
Institutions
- BGI Group (China) (CN)
- Anhui Medical University (CN)
- Hong Kong University of Science and Technology (HK)
- Peking University (CN)
- Shantou University (CN)
- Shantou University Medical College (CN)
- Peking University Shenzhen Hospital (CN)
- Shenzhen University Health Science Center (CN)
- Shenzhen Institute for Drug Control (CN)
- Shenzhen Pingle Orthopedic Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1007/s12672-025-02382-w
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking University